載入...
Gefitinib in Non Small Cell Lung Cancer
Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Hindawi Publishing Corporation
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3110340/ https://ncbi.nlm.nih.gov/pubmed/21660144 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/815269 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|